Cgpc, officially known as Chang Gung Pharmaceutical Corporation, is a prominent player in the pharmaceutical industry, headquartered in Taiwan (TW). Established in 1964, the company has made significant strides in the development and manufacturing of high-quality pharmaceutical products, including prescription medications and over-the-counter solutions. With a strong operational presence across Asia, Cgpc is renowned for its commitment to innovation and quality, particularly in the fields of biotechnology and generic pharmaceuticals. The company’s core offerings are distinguished by their rigorous adherence to international standards and a focus on patient safety. Cgpc has achieved notable recognition in the market, positioning itself as a trusted name in healthcare. Its dedication to research and development has led to several key milestones, solidifying its reputation as a leader in the pharmaceutical sector.
How does Cgpc's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Plastic production industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Cgpc's score of 23 is higher than 56% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2023, Cgpc reported total carbon emissions of approximately 15130000 kg CO2e for Scope 1, 16830000 kg CO2e for Scope 2, and 139490000 kg CO2e for Scope 3, amounting to a total of about 171000000 kg CO2e. This data reflects a comprehensive disclosure of emissions across all three scopes, indicating a commitment to transparency in their environmental impact. Comparatively, in 2022, Cgpc's emissions were significantly higher, with Scope 1 at approximately 151239000 kg CO2e, Scope 2 at about 168141000 kg CO2e, and Scope 3 reaching approximately 1394848000 kg CO2e. This suggests a notable reduction in emissions in 2023, particularly in Scope 1 and Scope 2, which is a positive step towards their climate commitments. Despite these reductions, Cgpc has not set specific reduction targets or initiatives, as indicated by the absence of documented reduction targets or SBTi commitments. The company operates under the umbrella of China General Plastics Corporation, which may influence its overall emissions strategy and reporting practices. Overall, while Cgpc has made strides in reducing its carbon footprint, the lack of formal reduction targets highlights an area for potential improvement in their climate strategy.
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Scope 1 | 5,066,000,000 | 0,000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 |
| Scope 2 | 9,425,000,000 | 0,000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 |
| Scope 3 | - | - | 0,000,000,000 | 0,000,000,000 | 000,000,000 |
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Cgpc has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.

